Nuclear factor-kappaB activation in axons and Schwann cells in experimental sciatic nerve injury and its role in modulating axon regeneration: studies with etanercept

J Neuropathol Exp Neurol. 2009 Jun;68(6):691-700. doi: 10.1097/NEN.0b013e3181a7c14e.

Abstract

Early inflammatory events may inhibit functional recovery after injury in both the peripheral and central nervous systems. We investigated the role of the inflammatory tumor necrosis factor/nuclear factor-kappaB (NF-kappaB) axis on events subsequent to sciatic nerve crush injury in adult rats. Electrophoretic mobility shift assays revealed that within 6 hours after crush, NF-kappaB DNA-binding activity increased significantly in a 1-cm section around the crush site. By immunofluorescence staining, there was increased nuclear localization of the NF-kappaB subunits p50 but not p65 or c-Rel in Schwann cells but no obvious inflammatory cell infiltration. In rats injected subcutaneously with etanercept, a tumor necrosis factor receptor chimera that binds free cytokine, the injury-induced rise in NF-kappaB DNA-binding activity was inhibited, and nuclear localization of p50 in Schwann cells was lowered after the injury. Axonal growth 3 days after nerve crush assessed with immunofluorescence for GAP43 demonstrated that the regeneration distance of leading axons from the site of nerve crush was greater in etanercept-treated animals than in saline-treated controls. These data indicate that tumor necrosis factor mediates rapid activation of injury-induced NF-kappaB DNA binding in Schwann cells and that these events are associated with inhibition of postinjury axonal sprouting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Axons / metabolism*
  • Axotomy / methods
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Electrophoretic Mobility Shift Assay / methods
  • Etanercept
  • GAP-43 Protein / metabolism
  • Gene Expression Regulation / drug effects
  • Immunoglobulin G / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Indoles
  • Male
  • NF-kappa B / metabolism*
  • Nerve Regeneration / drug effects*
  • Nerve Regeneration / physiology
  • Nerve Tissue Proteins / metabolism
  • Protein Subunits / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Schwann Cells / metabolism*
  • Sciatic Neuropathy* / drug therapy
  • Sciatic Neuropathy* / metabolism
  • Sciatic Neuropathy* / pathology
  • Time Factors

Substances

  • GAP-43 Protein
  • Immunoglobulin G
  • Immunologic Factors
  • Indoles
  • NF-kappa B
  • Nerve Tissue Proteins
  • Protein Subunits
  • Receptors, Tumor Necrosis Factor
  • DAPI
  • Etanercept

Grants and funding